XML 87 R32.htm IDEA: XBRL DOCUMENT v3.6.0.2
Quarterly Financial Data (Unaudited)
 12 Months Ended
Dec. 31, 2016
Quarterly Financial Information Disclosure [Abstract]  
Quarterly Financial Data (Unaudited)
    Quarterly Financial Data (Unaudited)
(In millions, except per share amounts)
First
Quarter
 
Second
Quarter
 
Third
Quarter
 
Fourth
Quarter
 
Total
Year
2016
(a)
 
(b)
 
(b) (c)
 
(b) (d) (e)
 
 
Product revenues, net
$
2,309.4

 
$
2,466.0

 
$
2,539.6

 
$
2,502.9

 
$
9,817.9

Revenues from anti-CD20 therapeutic programs
$
329.5

 
$
349.2

 
$
317.6

 
$
318.2

 
$
1,314.5

Other revenues
$
87.9

 
$
79.0

 
$
98.6

 
$
50.9

 
$
316.4

Total revenues
$
2,726.8

 
$
2,894.2

 
$
2,955.8

 
$
2,872.0

 
$
11,448.8

Gross profit (1)
$
2,413.8

 
$
2,523.9

 
$
2,538.9

 
$
2,493.5

 
$
9,970.1

Net income
$
969.2

 
$
1,048.4

 
$
1,030.2

 
$
647.9

 
$
3,695.7

Net income attributable to Biogen Inc.
$
970.9

 
$
1,049.8

 
$
1,032.9

 
$
649.2

 
$
3,702.8

Net income per share:
 
 
 
 
 
 
 
 
 
Basic earnings per share attributable to Biogen Inc.
$
4.44

 
$
4.79

 
$
4.72

 
$
3.00

 
$
16.96

Diluted earnings per share attributable to Biogen Inc.
$
4.43

 
$
4.79

 
$
4.71

 
$
2.99

 
$
16.93

Weighted-average shares used in calculating:
 
 
 
 
 
 
 
 
 
Basic earnings per share attributable to Biogen Inc.
218.9

 
219.1

 
218.9

 
216.6

 
218.4

Diluted earnings per share attributable to Biogen Inc.
219.3

 
219.4

 
219.4

 
217.0

 
218.8

(In millions, except per share amounts)
First
Quarter
 
Second
Quarter
 
Third
Quarter
 
Fourth
Quarter
 
Total
Year
2015
 
 
 
 
(f) (g)
 
(a) (h)
 
 
Product revenues, net
$
2,172.3

 
$
2,198.6

 
$
2,391.7

 
$
2,425.9

 
$
9,188.5

Revenues from anti-CD20 therapeutic programs
$
330.6

 
$
337.5

 
$
337.2

 
$
333.9

 
$
1,339.2

Other revenues
$
52.0

 
$
55.6

 
$
49.0

 
$
79.5

 
$
236.1

Total revenues
$
2,555.0

 
$
2,591.6

 
$
2,777.9

 
$
2,839.3

 
$
10,763.8

Gross profit (1)
$
2,242.6

 
$
2,305.5

 
$
2,467.9

 
$
2,507.5

 
$
9,523.4

Net income
$
820.2

 
$
924.8

 
$
1,019.5

 
$
828.7

 
$
3,593.2

Net income attributable to Biogen Inc.
$
822.5

 
$
927.3

 
$
965.6

 
$
831.6

 
$
3,547.0

Net income per share:
 
 
 
 
 
 
 
 
 
Basic earnings per share attributable to Biogen Inc.
$
3.50

 
$
3.94

 
$
4.16

 
$
3.77

 
$
15.38

Diluted earnings per share attributable to Biogen Inc.
$
3.49

 
$
3.93

 
$
4.15

 
$
3.77

 
$
15.34

Weighted-average shares used in calculating:
 
 
 
 
 
 
 
 
 
Basic earnings per share attributable to Biogen Inc.
235.0

 
235.3

 
232.2

 
220.4

 
230.7

Diluted earnings per share attributable to Biogen Inc.
235.6

 
235.7

 
232.6

 
220.8

 
231.2

(1) Gross profit is calculated as total revenues less cost of sales, excluding amortization of acquired intangible assets.
(a)
Net income and net income attributable to Biogen Inc., for the first quarter of 2016 and the fourth quarter of 2015, includes pre-tax restructuring charges totaling $9.7 million and $93.4 million, respectively related to the 2015 corporate restructuring program.
(b)
Net income and net income attributable to Biogen Inc. for the second, third and fourth quarters of 2016 includes pre-tax additional depreciation expense totaling $15.8 million, $15.7 million and $14.0 million, respectively, as part of our determination to cease manufacturing in our small-scale biologics manufacturing facility in Cambridge, MA as well as vacate our warehouse space in Somerville, MA. Our departure from these facilities has shortened the expected useful lives of certain leasehold improvements and other assets at these facilities.
(c)
Net income and net income attributable to Biogen Inc. for the third quarter of 2016 includes a pre-tax charge to research and development expense of $75.0 million for a license fee paid to Ionis as we exercised our option to develop and commercialize SPINRAZA.
(d)
Net income and net income attributable to Biogen Inc. for the fourth quarter of 2016 includes a pre-tax charge to research and development expense of $50.0 million for a milestone payment due to Eisai related to the initiation of a phase 3 trial for E2609.
(e)
Net income and net income attributable to Biogen Inc. for the fourth quarter of 2016 includes a pre-tax charge of $454.8 million related to the January 2017 settlement and license agreement with Forward Pharma.
(f)
Net income and net income attributable to Biogen Inc. for the third quarter of 2015 includes a pre-tax charge to research and development expense of $48.1 million recorded upon entering into the collaboration agreement with AGTC.
(g)
Net income attributable to Biogen Inc. for the third quarter of 2015 reflects the attribution of a $60.0 million charge to noncontrolling interests, net of tax, related to a milestone payment due Neurimmune upon the enrollment of the first patient in a Phase 3 trial for aducanumab.
(h)
Net income and net income attributable to Biogen Inc. for the fourth quarter of 2015 includes a pre-tax charge to research and development expense of $60.0 million recorded upon entering into the collaboration agreement with MTPC.